Articles
High-Throughput Screening Of Cell Lines Expressing Monoclonal Antibodies
May 26, 2009
•Feature Article: High-Throughput Screening Of Cell Lines Expressing Monoclonal Antibodies
By ChiChang Lee, Celia Ly, Tina Sauerwald, Thomas Kelly, and Gordon Moore
Recombinant proteins (r-proteins) are an important class of therapeutic agents. Monoclonal antibody technology has grown tremendously in the biopharmaceutical industry over the past two decades. With improvements in host-cell engineering, vector systems, media composition, and bioprocess optimization, productivity of mammalian cells can reach as high as grams per liter in bioreactor processes, an increase of more than 100-fold over titers reported for similar systems in the 1980s. Opportunities for improvement in expression systems still exist through further advancement in the technology of high-throughput screening.
Obtaining a stable clone for recombinant protein production usually requires cell transfection with an expression vector containing a gene of interest and a dominant genetic marker. Typically, a selectable marker such as a chemical resistance gene is transfected with a target gene of interest. Selection then is carried out in the presence of the specific toxic chemical. Cells that have taken up the expression-vector DNA survive in the corresponding selection media.
Reprinted with permission from BioProcess International 4(5):S32-S35 (May 2006)
Click Here To Download:•Feature Article: High-Throughput Screening Of Cell Lines Expressing Monoclonal Antibodies
